GB0717187D0 - Compositions comprising yersinia pestis antigens - Google Patents
Compositions comprising yersinia pestis antigensInfo
- Publication number
- GB0717187D0 GB0717187D0 GBGB0717187.9A GB0717187A GB0717187D0 GB 0717187 D0 GB0717187 D0 GB 0717187D0 GB 0717187 A GB0717187 A GB 0717187A GB 0717187 D0 GB0717187 D0 GB 0717187D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- compositions
- yersinia pestis
- pestis antigens
- antigens
- yersinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000607479 Yersinia pestis Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0717187.9A GB0717187D0 (en) | 2007-09-04 | 2007-09-04 | Compositions comprising yersinia pestis antigens |
| AU2008294413A AU2008294413A1 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising Yersinia pestis antigens |
| JP2010523608A JP2012501959A (ja) | 2007-09-04 | 2008-09-04 | Yersiniapestis抗原を含む組成物 |
| PCT/IB2008/003081 WO2009031043A2 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising yersinia pestis antigens |
| US12/733,488 US20100183674A1 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising yersinia pestis antigens |
| CA2698360A CA2698360A1 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising yersinia pestis antigens |
| EP08829437A EP2205274A2 (en) | 2007-09-04 | 2008-09-04 | Compositions comprising yersinia pestis antigens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0717187.9A GB0717187D0 (en) | 2007-09-04 | 2007-09-04 | Compositions comprising yersinia pestis antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0717187D0 true GB0717187D0 (en) | 2007-10-17 |
Family
ID=38640215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0717187.9A Ceased GB0717187D0 (en) | 2007-09-04 | 2007-09-04 | Compositions comprising yersinia pestis antigens |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100183674A1 (enExample) |
| EP (1) | EP2205274A2 (enExample) |
| JP (1) | JP2012501959A (enExample) |
| AU (1) | AU2008294413A1 (enExample) |
| CA (1) | CA2698360A1 (enExample) |
| GB (1) | GB0717187D0 (enExample) |
| WO (1) | WO2009031043A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| HRP20161352T1 (hr) | 2010-07-06 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Čestice nalik na virione za unos samoreplicirajućih molekula rna |
| CN103384515B (zh) | 2010-08-31 | 2017-02-15 | 诺华有限公司 | 适用于脂质体递送编码蛋白质的rna的脂质 |
| DK4226941T3 (da) | 2010-08-31 | 2024-12-02 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til levering af immunogen-kodende rna |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| WO2012103421A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Adjuvant nanoemulsions with crystallisation inhibitors |
| ES2785108T3 (es) | 2011-03-24 | 2020-10-05 | Glaxosmithkline Biologicals Sa | Nanoemulsiones adyuvantes con fosfolípidos |
| CN103764121A (zh) | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| US20140255472A1 (en) | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| EP2897635A1 (en) | 2012-09-18 | 2015-07-29 | Novartis AG | Outer membrane vesicles |
| EA201891018A1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| EP3083579B1 (en) | 2013-12-19 | 2022-01-26 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| EP3188760B1 (en) | 2014-09-05 | 2023-12-06 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| AU2021360494A1 (en) | 2020-10-14 | 2023-05-18 | George Mason Research Foundation, Inc. | Ionizable lipids and methods of manufacture and use thereof |
| EP4387596A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| EP4387597A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0815235T3 (da) * | 1995-03-13 | 2003-04-22 | Secr Defence | Vacciner mod pest |
| US7776336B2 (en) * | 2005-10-25 | 2010-08-17 | Novartis Vaccines And Diagnostics Srl | Compositions comprising Yersinia pestis antigens |
-
2007
- 2007-09-04 GB GBGB0717187.9A patent/GB0717187D0/en not_active Ceased
-
2008
- 2008-09-04 WO PCT/IB2008/003081 patent/WO2009031043A2/en not_active Ceased
- 2008-09-04 US US12/733,488 patent/US20100183674A1/en not_active Abandoned
- 2008-09-04 EP EP08829437A patent/EP2205274A2/en not_active Withdrawn
- 2008-09-04 CA CA2698360A patent/CA2698360A1/en not_active Abandoned
- 2008-09-04 JP JP2010523608A patent/JP2012501959A/ja active Pending
- 2008-09-04 AU AU2008294413A patent/AU2008294413A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012501959A (ja) | 2012-01-26 |
| WO2009031043A3 (en) | 2009-08-13 |
| US20100183674A1 (en) | 2010-07-22 |
| CA2698360A1 (en) | 2009-03-12 |
| EP2205274A2 (en) | 2010-07-14 |
| WO2009031043A2 (en) | 2009-03-12 |
| AU2008294413A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0717187D0 (en) | Compositions comprising yersinia pestis antigens | |
| GB0714963D0 (en) | Compositions comprising antigens | |
| IL247741A0 (en) | pharmaceutical preparations | |
| IL202648A0 (en) | Antibody formulations | |
| IL202950A0 (en) | Antibody formulations | |
| EP2173163A4 (en) | ANTIBODY FORMULATIONS | |
| GB0711656D0 (en) | Formulations | |
| GB0716385D0 (en) | Formulations | |
| EP2222313A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ZA200908969B (en) | Formulations | |
| GB0809979D0 (en) | Formulations | |
| GB0711957D0 (en) | Formulations | |
| EP2146695A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB0707127D0 (en) | Pharmaceutical compositions | |
| GB0810232D0 (en) | Formulations | |
| GB0709811D0 (en) | Pharmaceutical compositions | |
| GB0700135D0 (en) | Vaccine | |
| GB0710574D0 (en) | Antifouling composition | |
| GB0712454D0 (en) | Pharmaceutical compositions | |
| EP2167635A4 (en) | ANTIBODY FORMULATIONS | |
| GB0705179D0 (en) | Formulations | |
| GB2454923B (en) | Pharmaceutical compositions | |
| IL201394A0 (en) | Niacin - based pharmaceutical compositions | |
| GB0702363D0 (en) | Vaccine composition | |
| GB0723900D0 (en) | Lyophillised antigen composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |